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Innate Immune Cell–Produced IL-17 Sustains
Inflammation in Bullous Pemphigoid
Se´bastien Le Jan1,2, Julie Ple´e1,2, David Vallerand1, Aure´lie Dupont3, Elodie Delanez1, Anne Durlach4,
Patricia L. Jackson5, J. Edwin Blalock5, Philippe Bernard1,2,6 and Frank Antonicelli1,6
Bullous pemphigoid (BP) is an autoimmune skin disease characterized by the binding of autoantibodies to
components of the hemidesmosome structure, resulting in an inflammatory response and subepidermal blister
formation. To investigate the role of immune orientation in the inflammatory processes associated with disease
progression, blister fluid, serum, and biopsy specimens were collected from 31 consecutive BP patients. Blister
fluids displayed high levels of IL-6, IL-17, IL-22, and IL-23, whereas transforming growth factor-b was increased in
BP sera. However, neither immunocytochemistry on a trans-differentiation model of IL-17-producing peripheral
blood mononuclear cells nor immunohistochemistry on BP biopsy specimens could demonstrate the presence
of T helper type 17 lymphocytes. Instead, innate immune cells, especially neutrophils, produced IL-17 at the skin
lesional site. Of note, superpotent topical corticosteroid application quickly and markedly reduced both IL-17
expression and clinical signs of BP. Consistently, IL-17 upregulated matrix-metalloprotease-9 and neutrophil
elastase expression, two proteases involved in blister formation, thereof further demonstrating its role in
the progress of BP. Finally, IL-17-induced matrix degradation, originated from neutrophil activation, initiated the
formation of an amplification loop of the inflammatory response that could represent the underlying
phenomenon leading to the maintenance and even disease extent. Thus, our results could open new therapeutic
strategies for BP patients.
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INTRODUCTION
Bullous pemphigoid (BP), the most common autoimmune
blistering skin disease in developed countries (Langan et al.,
2008), is characterized by the binding of autoantibodies to
two major proteins of the dermal–epidermal junction: BP180
and BP230. Animal model studies showed the critical role of
autoimmune complexes in triggering the inflammatory pro-
cess, leading to the dermal–epidermal junction disruption and
subsequently to blister formation (Liu et al., 1993; Hirose
et al., 2011; Oswald et al., 2012).
BP, considered as a T helper type 1 (Th1)/Th2 cell–mediated
disease with a predominance of Th2 cells, is associated with
BP180/BP230 autoantibody production. However, autoanti-
body binding cannot explain all of the diverse clinical
features observed in this disease. In particular, after a few
weeks of treatment with either systemic or superpotent topical
corticosteroid (STC), BP patients are cleared of all clinical
symptoms or signs, whereas anti-BP180 autoantibody serum
level is still high (Schmidt et al., 2000; Di Zenzo et al.,
2008; Fichel et al., 2013). A dense lesional infiltration of
polymorphonuclear (PMN) cells along with the production of
proteases such as matrix-metalloprotease-9 (MMP-9) or
neutrophil elastase (NE) were shown to be crucial in the
extension of the disease (Liu et al., 1997; Liu et al., 1998; Liu
et al., 2000a). However, the mechanisms involved in the
recruitment of the inflammatory cells and in the regulation of
these proteases in BP are still not complete and remain to be
better defined at the molecular level.
Recently, compelling evidence highlighted the major con-
tribution of Th17 cells in autoimmune diseases (Kleinewietfeld
and Hafler, 2013). In contrast to Th1 and Th2 cells, the
recently defined Th17 lineage displays certain plasticity with
respect to cytokine environment (Weaver et al., 2007;
Hoechst et al., 2011; Lee et al., 2009). Although regulatory
T cells and Th17 cells functionally antagonize each other,
they both require transforming growth factor-b (TGF-b)
in their early differentiation from naive precursors (Manel
et al., 2008; Mangan et al., 2006). However, conversely to
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regulatory T cells, a proinflammatory cytokines network such
as IL-1 or IL-6, in concert with high levels of IL-23, is further
required for late Th17 polarization. Besides Th17 cells, it has to
be mentioned that several innate immune cell types such as
innate lymphoid cells (natural killer and gd T cells),
neutrophils, and mast cells can also produce IL-17 in
inflammatory conditions (Cua and Tato, 2010; Lin et al.,
2011; Keijsers et al., 2013). In BP, some recent studies using
immunohistochemical approaches have suggested the
presence of Th17 cells at the site of the dermal–epidermal
detachment (Arakawa et al., 2011; Fischer-Stabauer et al.,
2012; Zebrowska et al., 2013). Although Th17 cells are
characterized by their ability to produce high levels of IL-17
(Harrington et al., 2005; Park et al., 2005), the mechanisms
leading to IL-17 production and its link with blister formation
are still unraveled in BP.
A long-known outcome of IL-17 biological cascade is the
production of inflammatory molecules such as cytokines
(tumor necrosis factor-a, IL1-b, GM-CSF, IL-6), chemokines
(IL-8), and proteases (MMP-9) (Miossec and Kolls, 2012),
which are a hallmark of the inflammatory response
associated with BP (Kasperkiewicz and Zillikens, 2007). In
this study, the evaluation of inflammatory cytokine expression
(IL-17, IL-22, IL-6, IL-23), effector or marker of tissue damage
(MMP-9 and the tripeptide Pro-Gly-Pro (PGP)), and molecules
regulating the inflammatory network, such as transforming
growth factor-bin both serum and blister fluid samples,
revealed an amplification loop originated by neutrophil-
induced IL-17 that could favor the perpetuation or even the
extent of the disease.
RESULTS
IL-17 and MMP-9 expression in BP
Using specific ELISA, we provided evidence for a significantly
increased level of IL-17 in blister fluid (BF) compared with BP
serum from 31 consecutive patients (Figure 1a), whereas no
variation was observed between the level of IL-17 in serum
from BP patients and from age- and sex-matched controls.
Concomitantly, we analyzed by gel zymography the levels of
secreted MMP-9 both in blister fluids and sera obtained from
BP patients at the time of diagnosis. MMP-9 secretion was
significantly increased in BP sera (n¼8) compared with control
(n¼6), and it was even higher in blister fluids (n¼10)
compared with BP sera (Figure 1b), supporting results obtained
by Niimi et al., (2006).
To seek a potential relationship between IL-17 and MMP-9,
as well as their involvement in the BP pathological processes,
we investigated whether STC treatment could affect their
expression at the lesional site. In this line, BF from three BP
patients were collected before and after the early days of
treatment (Joly et al., 2009). We observed a marked decrease
of both IL-17 and MMP-9 levels after only few days of STC
treatment, varying from 2 to 4 days (Figure 1c). Concomi-
tantly, STC treatment induced a fast drop in the number of
daily new blisters, whereas the level of anti-BP180/BP230
autoantibodies remained quite stable over this short period of
time, emphasizing the importance of the inflammation process
in BP blister occurrence.
IL-17-associated proinflammatory cytokines in BP
To further characterize the mechanisms associated with IL-17
expression in BP, we measured the levels of TGF-b, IL-6, IL-
22, and IL-23, which are cytokines associated with the
developmental plasticity of Th17 precursors in both sera and
BF collected from BP patients at the time of diagnosis
(Figure 2). TGF-b, known to prime Th17 orientation, was
significantly overexpressed in BP sera compared with BF and
with serum from controls. In contrast, levels of IL-6, IL-22, and
IL-23, three cytokines associated with Th17 cell terminal
differentiation, were significantly higher in BF compared
with BP sera, suggesting a progressive differentiation toward
IL-17-producing cells, starting first in the blood and then
achieved in situ nearby the site of lesion. In our series, the
level of these three cytokines was not statistically increased in
BP serum compared with controls.
IL-17 expression by innate immune cells in BP
To verify our suspected mechanism of IL-17 production
through a cell trans-differentiation process from blood to
lesional skin, we established a BP-related new working model
to illustrate IL-17 overexpression. To that purpose, peripheral
blood mononuclear cells (PBMCs) were isolated from healthy
subjects (n¼ 5), and were consecutively stimulated with BP
sera for 48 hours followed by an incubation with BF for an
additional 48 hours. To determine the respective role of BP
serum and BF in il17 and mmp-9 expression, cells from the
same subject stimulated with BP serum or autologous serum
and combined with BF were compared with cells stimulated
with either autologous or BP serum alone. mmp-9 expression
was analyzed concomitantly to il17 by quantitative PCR. Inter-
individual variability in mmp-9 and il17 expression was
observed in response to BP sera alone as compared with
autologous stimulation (Figure 3a). When blister fluid was
consecutively added to cells initially stimulated with auto-
logous serum, il17 but not mmp-9 expression increased in
all PBMCs tested (Figure 3b). Remarkably, consecutive
PBMC stimulation with BP serum and BF induced a substantial
increase of mmp-9 expression (Figure 3c). However, replace-
ment of autologous serum by BP serum did not magnify
the effects of BF on il17 expression (Figure 3b and c). Using
our model, colocalization analysis by immunocytochemistry
revealed that none of the CD3þ cells expressed IL-17
(Figure 3d). Although IL-17 was highly expressed by infiltrated
cells in the upper dermis of lesional skin of a BP patient
(Figure 4a), immunohistochemistry analysis of biopsy speci-
mens of BP showed no double-positive cells for CD3 and
IL-17 in situ (Figure 4b). Instead, innate immune cells such as
infiltrated myeloperoxidase-positive neutrophils and tryptase-
positive mast cells strongly expressed IL-17 (Figure 4c and d).
IL-17 induced the expression of MMP-9 and NE
We then wondered whether IL-17 could modulate MMP-9
expression and activation from both PBMCs and PMN cells.
IL-17 used at a concentration equivalent to those measured in
BF (0.2 ng ml1) significantly increased MMP-9 secretion from
PBMCs and PMN cells (Figure 5a–c). In PBMCs, MMP-9
protease, resulting from an increased messenger RNA
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expression (Figure 5b), was present under both the pro-MMP-9
and the active form, as demonstrated by the appearance of a
second band on gel zymography (Figure 5a). Concurrently to
MMP-9 activation in PBMCs, IL-17 also significantly increased
the human NE (HNE) activity released from PMN cells
(Figure 5d).
PGPs from BP blister fluid generate a neutrophil-mediated
amplification loop
We previously showed that MMP-9 cleaved the collagenic
hemidesmosomal protein BP180 into small peptides (Verraes
et al., 2001). In silico analysis of human BP180 protein
sequence identified, within the C-Terminal domain of
BP180, 47 PGP motifs (Figure 6a) that are able to chemoattract
neutrophils (Weathington et al., 2006; Pfister et al., 1995).
Analysis by mass spectrometry revealed that PGP levels were
significantly elevated in BP serum compared with serum from
healthy controls, and were even higher in BF, showing a
gradient of these peptides from the tissue lesion until the blood
circulation (Figure 6b). Compared with the control peptide
PGG, PGP but also PGPPGP and AcPGP peptides significantly
enhanced PMN cell chemotaxis (Figure 6c). However, only
PGP peptides significantly induced HNE release from PMN
cells (Figure 6d), supporting their role in an amplifying
inflammatory loop in BP.
DISCUSSION
Strengthening the importance of an inflammatory response
linked to MMP-9 expression in blister formation in BP (Liu
et al., 1998; Verraes et al., 2001), we here characterized an IL-
17-induced MMP-9-associated inflammatory response
controlled by innate immune cells. We emphasized the
formation of an autoamplification loop that could self-
reinforce the chronic inflammatory state and therefore
exacerbate the tissue damages observed in BP patients with
severe disease.
Elevated levels of IL-17 in blister fluids support recent
studies that highlighted the presence of IL-17-producing cells
in BP (Arakawa et al., 2011; Fischer-Stabauer et al., 2012;
Zebrowska et al., 2013), and suggested that BP regulation was
beyond the Th1/ Th2 paradigm. Although our study confirmed
the presence of transforming growth factor-bin BP serum
(D’Auria et al., 1999), and of IL-6 in BF (Rhodes et al.,
1999), but also described the expression of IL-23 in BF, neither
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Figure 3. Lymphocytes do not express IL-17 in a trans-differentiation model. Matrix-metalloprotease-9 (mmp-9) and il17 gene expression was analyzed by
real-time quantitative PCR in freshly and healthy isolated peripheral blood mononuclear cells (PBMCs) (n¼ 5). PBMCs were treated with either autologous or
bullous pemphigoid (BP) serum (a). PBMCs were consecutively treated with either autologous (b) or BP serum (c) for 48 hours and then stimulated or not stimulated
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immunohistochemistry on BP biopsy specimens nor
immunocytochemistry approaches in our ex vivo model
supported the hypothesis of an immune Th17 T-cell
orientation, as proposed by Arakawa et al., (2011). These
authors used CD4 as a biological marker to characterize the
lymphocytes at the site of lesion. Nevertheless, CD4 is also
expressed by monocyte/macrophage, dendritic cells, and
even by neutrophils in some conditions. Furthermore, in the
study by Arakawa et al., (2011), histological counterstain
technique was used to identify IL-17-producing cells. In
contrast, the use of CD3, a specific T-cell marker associated
with immunofluorescence colocalization, did not allow the
detection of any IL-17-producing lymphocytes in our work.
Accordingly, PBMC trans-differentiation using both serum and
BF from BP patients could not illustrate the presence of IL-17
expression by lymphocytes. Hence, as CD4 is also expressed
by innate immune cells such as macrophages, the results
obtained in our study and that of theirs would rather advocate
for the role of innate immune cells in BP.
Our results provided compelling reasons to explore outside
the Th17 cell paradigm to explain the high production of IL-17
at the site of lesion in BP. Actually, IL-17, originally thought to
be produced exclusively by T cells (Fossiez et al., 1996), is
also secreted by a variety of innate cells such as macrophages,
neutrophils, and dendritic cells (Korn et al., 2009; Cua and
Tato, 2010; Biswas et al., 2003). Although the use of our
PBMC trans-differentiation model argued for a production of
IL-17 by macrophages, in situ analysis demonstrated a large
amount of IL-17-producing neutrophils. Besides, mast cells
also expressed high levels of IL-17, reinforcing the major role
of innate immune cell in the inflammatory response in BP. On
the basis of a recent report (Taylor et al., 2014), one could
hypothesize that an initial IL-17 expression could
subsequently stimulate neutrophils to produce even more IL-
17 in an autocrine way, although such a mechanism still
needs to be demonstrated in BP.
Although it sounds clear that innate immune cells are
involved in IL-17 production in BP, the underlying mechan-
isms are still unraveled. Autoantibodies form tissue-deposited
immune complexes that directly activate neutrophils via their
FcgR (Mayadas et al., 2014). Furthermore, it was recently
shown in rheumatoid arthritis that immune complex–activated
neutrophils triggered the production of IL-17 (Katayama et al.,
2013). An il17 messenger RNA increase in purified neutro-
phils after administration of anti-neutrophil cytoplasmic
autoantibodies was also reported (Hoshino et al., 2008).
Then, in BP, similar to that in other autoimmune diseases,
neutrophils could produce IL-17 as a result of ‘‘sterile’’ injury
subsequent to barrier tissue alteration following antigen
processing. As mentioned above, IL-23 was enhanced in BF
from BP patients. Constitutive expression of IL-23 receptor is a
common characteristic of many IL-17-producing innate cells
(Martin et al., 2009; Yoshiga, 1998), although it is not known
whether neutrophils express this receptor on their surface
yet. Other inflammatory processes such as leukotriene B4
application were also shown to induce neutrophil IL-17
expression (Keijsers et al., 2013), illustrating the multiplicity
of pathways able to induce IL-17 production by neutrophils.
Although our model study is inadequate to demonstrate the
primum movens event put forward by skin sentinel cells that
would lead to IL-17 production in BP, we emphasized the role
of neutrophils in IL-17 production.
IL-17 enhanced the expression of the HNE enzyme and of
the MMP-9 protease both under its latent and active forms in
PBMC and PMN cells. In BP, MMP-9 and HNE production is
crucial for blister formation (Liu et al., 1998; Liu et al., 2000a;
Verraes et al., 2001). By inactivating the a1-proteinase
inhibitor, MMP-9 enables HNE activity, the main enzyme
responsible of BP180 degradation in BP (Liu et al., 2000b).
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Figure 4. IL-17 is produced by neutrophils and mast cells but not by
lymphocytes in the skin of bullous pemphigoid (BP) patients. Punch biopsies
of skin from patients with BP were subjected to IL-17 staining alone (a) or
double immunofluorescence staining for IL-17 (green) and either CD3 (b),
myeloperoxidase (MPO) (c), or tryptase (d) in red with Hoescht counterstain
(blue). These high-power fields at the dermo–epidermal junction (DEJ) illustrate
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CTR: negative control in which primary antibodies were not added. B, blister;
D, dermis; E, epidermis. Scale bars ¼ 100mm (a) and 10mm (b–d).
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Furthermore, IL-17 upregulates the expression of key cytokines,
chemokines, and proteases involved in the recruitment of
neutrophils, macrophages, and lymphocytes, and drives the
degradation of extracellular matrix at the site of lesion (Onishi
and Gaffen, 2010). It is noteworthy that matrix molecule
degradation also participates in BP progression. MMP-9 and
NE cleave the extracellular domain of BP180 (Verraes et al.,
2001; Sta˚hle-Ba¨ckdahl et al., 1994) (Lin et al., 2012). The
release of a 12-kDa digestion product from murine BP180
displayed chemo-attractive effects on neutrophils (Lin et al.,
2012). Accordingly, and for the first time in BP to our
knowledge, we evidenced the presence of high levels of the
tripeptide PGP in BF, present all along the extracellular
collagen-like domain of BP180. Similar to that in other
tissues (Weathington et al., 2006; Pfister et al., 1995; Xu
et al., 2011), these tripeptides attract and activate neutrophils
in the skin. PGP could therefore generate a self-propagating
chronic neutrophilic inflammation in BP. Indeed, it has been
shown with the use of several animal models that blister
formation originates from autoantibodies binding to the
hemidesmosomal protein BP180 leading to PMN cell
recruitment and activation, followed by proteases release at
the site of lesion. To that scheme, our results add an
amplification loop in which matrix degradation product could
autoamplify the inflammatory reaction, independently of the
autoimmune response. Upon IL-17 recruitment and activation,
neutrophils produce even more IL-17 and release protease,
leading to matrix degradation and to the generation of matrix
peptides that further favor neutrophil recruitment and activation
at the site of skin lesion. Then, the inflammatory process
leading to blister formation would become independent of
the immune complex formation, as originally demonstrated in
the progress of BP disease. According to previous models,
beyond the Th1-polarization associated with disease initiation,
which lead to the production of pathogenic anti-BP180
antibodies (Kasperkiewicz and Zillikens, 2007), inflammatory
factors released by innate cells could favor disease perpetuation
or even extent of BP.
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Figure 5. IL-17 regulates protease expression and activation in PBMC and PMN cells. (a) Gelatin zymography was used to detect matrix-metalloprotease-9 (MMP-
9) gelatinolytic activity in IL-17-treated peripheral blood mononuclear cells (PBMCs), and quantification (n¼ 7) was done. (b) mmp-9 expression was measured by
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the error bars denote the mean±SEM. Wilcoxon paired test was used for statistics.
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The IL-17-associated inflammatory autoamplification loop
in BP was in line with the blister content analysis before and
after treatment with steroids. Indeed, STC treatment very
efficiently reduced blister formation and MMP-9 and IL-17
production within the first days of treatment. Accordingly, in a
BP experimental model, methylprednisolone reduced autoan-
tibody-induced PMN cell activation (Hellberg et al., 2013).
Actually, patients’ early clinical signs clearing upon STC
treatment were actually bound to the control of the IL-17-
associated inflammatory phase of this autoimmune disease. Of
note, it has been reported that activation of IL-17 receptor on B
cells promotes B-cell differentiation to autoantibody-producing
plasma cells (Doreau et al., 2009). Then, the expression of IL-
17 could link innate and adaptive immunity in autoimmune
diseases such as BP, and blocking the IL-17 proinflammatory
amplification processes could disrupt the long-term signals
such as release of cryptic antigenic peptides during matrix
degradation and lymphocyte B activation, feeding the
inflammatory and autoimmune responses, respectively.
Hence, our results relative to BP are similar to those of most
of the IL-17 studies, which focused on its ability to drive
inflammation in autoimmune disorders including multiple
sclerosis, Crohn’s disease, rheumatoid arthritis, psoriasis, and
ankylosing spondylitis (Miossec and Kolls, 2012). It would
then be of interest to decipher whether such amplification
loops of inflammation are also involved in these diseases.
In conclusion, our study documents the immune and
inflammatory responses in BP, and suggests a mechanism that
leads to the generation of IL-17-producing cells and over-
expression of proteases. This mechanism could represent the
underlying phenomenon that leads to disease extent in BP,
which has been shown to be associated with further relapse in
these patients (Fichel et al., 2013). Such a process is therefore
of clinical importance, and similarly preclinical studies
supporting a role for IL-17 in autoinflammatory or auto-
immune diseases led to current clinical trials designed to
block IL-17, its inducers (i.e. IL-23, IL-6), or the IL-17 receptor
(IL-17 receptor) in autoimmunity (Miossec and Kolls, 2012;
Iwakura et al., 2011). Hence, targeting IL-17 signaling cascade
could be a promising therapeutic strategy in the treatment of
an inflammation response associated with bullous auto-
immune diseases including BP.
MATERIALS AND METHODS
Study design
This prospective, monocentric, observational, and translational study
was conducted in the dermatology French department of Reims
University Hospital, which belongs to the French Referral Center for
Autoimmune Bullous Diseases (Reims, Rouen, Limoges), and in the
dermatology department of the Reims university of Medicine. Thirty-
one consecutive patients with BP admitted from 2009 to 2011 were
assessed (8 men and 23 women; mean age 80.8 years, range 53–96
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Figure 6. PGP peptides from bullous pemphigoid (BP) biological fluids affect polymorphonuclear (PMN) cell chemotaxis and PMN cell activation.
(a) Pro-Gly-Pro (PGP) sequences (in red) within the C-terminal part of collagen XVII protein sequence. (b) PGP peptide detection by electrospray ionization liquid
chromatography–tandem mass spectrometry in serum from patients without inflammatory and/or autoimmune diseases, BP serum, and blister fluid (BF). Data
are shown as a box-and-whisker plot. The median of the distribution is indicated by the horizontal line in the box. Mann–Whitney test was used for statistics.
(c) Chemotactic migration of PMN cells induced by PGP, PGPPGP, or AcPGP peptides (10mM) in a Boyden chamber chemotaxis assay (n¼3). (d) Human
neutrophil elastase (HNE) activities in PGP, PGPPGP, or AcPGP-stimulated PMN cells relative to control (n¼3). The error bars denote the mean± SEM. Student’s
t-test was used for statistics.
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years). The diagnosis of BP was established on the basis of clinical
and immunohistological criteria (Di Zenzo et al., 2012; Vaillant et al.,
1998). Biological samples (serum and blister fluid) were collected at
the time of diagnosis and until the clinical signs cleared upon steroid
treatment (blister fluid). All voluntary subjects gave their written
informed consent before inclusion in the study. Serum samples from
age- and sex-matched patients without inflammatory and auto-
immune diseases admitted to the trauma department of the Reims
University Hospital were used as controls.
Ethics statement
The study was approved by the Ethics Committee of the University
Hospital of Reims (institutional review board; 14 April 2009); patients
or their relatives were informed by letter and gave their written
consent, in accordance with the Helsinki Declaration.
Cell isolation and ex vivo stimulation
PBMCs and PMN cells were obtained by density-gradient centrifuga-
tion from EDTA-treated whole blood using a density-gradient medium
(Granulosep, Eurobio-Abcys, Courtaboeuf, France).
To mimic in vivo conditions, freshly isolated PBMCs from healthy
subjects were cultured in RPMI medium with 25% BF for 48 hours,
consecutively to a stimulation with either 25% autologous serum or
25% BP serum for 48 hours before being harvested for gene
expression analysis (n¼ 10) or before being cytospun for immuno-
fluorescence studies. Control PBMCs were cultured with either 25%
autologous serum or BP serum alone.
PBMCs and PMN cells isolated from BP patients were stimulated
for 1 hour, by either IL-17, or PGG/PGP peptides (100 nM) before to
harvest cells for gene expression analysis and medium for MMP-9
secretion or HNE activity analysis.
Quantitative real-time reverse-transcriptase–PCR
RNA was extracted with the TriReagent (Molecular Research Center,
Cincinnati, OH) from freshly isolated PBMC control or PBMCs
stimulated for 24 hours or 96 hours, respectively, with IL-17 at different
concentrations (0.1, 0.2, and 1 ng ml 1) or with the combination of BP
serum and BF. Protocol for the quantitative real-time reverse-transcrip-
tase–PCR is described in detail in Supplementary Data online.
Determination of cytokine levels
Cytokine (IL-17, IL-22, TGF-b, IL-23, and IL-6) and autoantibody
(BP230 and BP180) concentrations were determined in BP serum and/
or BF according to the manufacturer’s instructions of the respective
commercially available ELISA assays (R&D Systems Europe, Abing-
don, UK and Clinisciences, Nanterre, France, respectively).
Electrospray ionization liquid chromatography–tandem mass
spectrometry for PGP detection
Electrospray ionization liquid chromatography–tandem mass spectro-
metry for PGP detection was performed as described in (Hardison
et al., 2009). PGPs were measured in blister fluids and serum samples
from BP patients and age- and sex-matched patients without
inflammatory and autoimmune diseases.
Zymography
Gel zymography was performed on serum samples (n¼ 8) and blister
fluids (n¼ 10) from BP patients or on PBMCs and PMNs stimulated or
not stimulated with IL-17 (n¼ 7). Serum samples from age-matched
patients without inflammatory and autoimmune diseases were used as
controls (n¼ 6). MMP activity analysis was performed as described
previously (Emonard and Hornebeck, 1997).
HNE activities
Human elastase activity was assessed using the N-(Methoxysuccinyl)-
Ala-Ala-Pro-Val-p-4-nitroanilide (Sigma-Aldrich, Saint-Quentin Fallavier,
France) as substrate. Levels of enzyme activity were determined from
50ml of culture media issued from neutrophils stimulated or not
stimulated with IL-17. The amount of para-nitro-anilide was measured
each minute for 15minutes at 25 1C by spectrometry at 405nm (HTS
700 Plus, Perkin Elmer, Waltham, MA).
Neutrophil chemotaxis assay
Neutrophil migration assay in response to control peptide PGG or to
the different chemoattractants PGP, PGPPGP, and AcPGP was
performed using a Boyden chamber (5mm pore size; Merck Millipore,
Darmstadt, Germany). The migrated neutrophils (located at the
bottom side of the membrane) were counted from three different
fields using Eclipse E400 microscope from Nikon (Tokyo, Japan).
PGG and PGP peptides were purchased from Genescript (Piscataway,
NJ), with purity over 95%.
Immunohistochemistry
All peri-lesional skin biopsies performed in patients with BP before
introduction of any corticosteroid treatment were obtained from the
Pathological Anatomy Department of Reims Hospital. Detailed
procedures for analysis by immunohistochemistry or immunocyto-
chemistry are described in the Supplementary Data online.
Statistical analysis
Descriptive statistics such as means, SDs, or SEMs were conducted for
all quantitative measures. As the distribution of the variables that we
analyzed could not be assumed to be normal and some of the groups
examined were small, we used nonparametric testing to compare
populations in this study. Comparisons between the two groups were
performed using the exact Wilcoxon signed-rank test for paired data
and the Mann–Whitney test for unpaired data. The results were
considered significant if P-values were 0.05 or less.
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